New drug could beat steroids for saving sight in thyroid eye disease

NCT ID NCT07594912

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments given after emergency eye surgery for people with thyroid eye disease who have vision loss. One group gets teprotumumab, a newer drug that blocks a growth factor, and the other gets high-dose steroids. The goal is to see which one better improves eyesight over 24 weeks. About 60 adults aged 18 to 65 will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teprotumumab (a drug that blocks a growth factor) and methylprednisolone (a steroid)
What this could lead to: If it works, this could offer a more effective treatment to save vision in people with severe thyroid eye disease.
What could go wrong: This is a small, early-phase trial with only 60 people, so results may not apply to everyone. Teprotumumab can cause side effects like muscle cramps or hearing problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES OPHTHALMOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy optic nerve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAVES OPHTHALMOPATHY OPTIC NEUROPATHY THYROID EYE DISEASE (TED)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhongshan Ophthalmic Center, Sun Yat-sen University

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.